Search results for "Recurrence"

showing 10 items of 1036 documents

MRI abnormalities following repeated and incoming seizures.

2010

Abstract Neuroimaging, an important diagnostic tool frequently used in the evaluation of patients with epilepsy, has mainly the aim to identify structural abnormalities needing a treatment and to contribute to the definition of the aetiology. Brain magnetic resonance imaging (MRI) in epilepsy is more sensitive than computerized tomography (CT) scan for detecting abnormalities. Status epilepticus (SE) and repeated incoming seizures may determine extensive and transient or long lasting pronounced MRI changes. We describe a case of a 41-year-old woman with a history of brain neoplasm, whose contrast-enhanced MRI images following repeated and incoming seizures were characterized either by rever…

Long lastingAdultmedicine.medical_specialtyClinical NeurologyStatus epilepticusMRI abnormalityEpilepsyNeuroimagingRecurrenceSeizuresMedicineHumansBrain magnetic resonance imagingStatus epilepticusbusiness.industryElectroencephalographyGeneral Medicinemedicine.diseaseSeizureMagnetic Resonance ImagingNeurologyEtiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)TomographyRadiologymedicine.symptombusinessBrain neoplasmEpilepsy MRISeizure
researchProduct

Long-lasting rewarding effects of morphine induced by drug primings.

2005

To evaluate the persistence of the rewarding effects of morphine, the acquisition, maintenance, extinction and reinstatement of a conditioned place preference (CPP) was assessed in OF1 mice. In Experiment 1, the persistence of morphine-induced CPP was evaluated weekly. Mice showed CPP after four sessions of conditioning with 5, 10, 20 and 40 mg/kg of morphine, which lasted 0, 1, 2 and 4 weeks, respectively. In Experiment 2, after four sessions of conditioning with 40 mg/kg of morphine, the effects of four schedules of extinction differing in the time interval (2, 4, 6 or 8 weeks) between sessions were evaluated. CPP was no longer evident after 8 weeks for the groups examined each 2 or 8 wee…

Long lastingDrugMaleTime Factorsmedia_common.quotation_subjectMice Inbred StrainsPharmacologyExtinction PsychologicalMiceRewardRecurrenceConditioning PsychologicalmedicineAnimalsMolecular Biologymedia_commonBrain ChemistryMorphineGeneral NeuroscienceExtinction (psychology)Conditioned place preferenceAnalgesics OpioidAnesthesiaChronic DiseaseMorphineConditioningNeurology (clinical)PsychologyMorphine DependenceDevelopmental Biologymedicine.drugBrain research
researchProduct

Low-grade fever: how to distinguish organic from non-organic forms.

2010

Summary Background and aim:  Low-grade fever (LGF) is defined as a body temperature between 37.5 and 38.3 °C, which is below the classical value reported for fever of unknown origin (FUO). We attempted to characterise its epidemiology, aetiology and clinical aspects to improve the methodological approach to diagnosis. Design and Methods:  We reviewed and evaluated a survey of patients with LGF, followed as outpatients of our Department, a tertiary referral centre from 1997 to 2008. The same classifications were applied for classical FUO, and in the patients diagnosed with LGF, we also investigated for habitual hyperthermia (HH). Results:  Seventy-three patients were selected and divided int…

Low-grade feverAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaFeverorganicPhysical examinationGastroenterologyGroup BLow-grade feverBody TemperatureDiagnosis DifferentialYoung AdultRecurrenceInternal medicineEpidemiologymedicineHumansFever of unknown originYoung adultLow-grade fever; organic; functionalPathologicalPhysical Examinationmedicine.diagnostic_testbusiness.industryGeneral Medicinemedicine.diseaseSurgeryfunctionalEtiologyFemalebusinessInternational journal of clinical practice
researchProduct

Frequent detection of cytomegalovirus (CMV) DNA in the lower respiratory tract in CMV-seropositive pediatric patients with underlying chronic broncho…

2012

Abstract Cytomegalovirus (CMV) may be a relevant cause of morbidity in patients displaying various inflammatory diseases. In this study, it was investigated whether CMV DNA is detected in the lower respiratory tract and the systemic compartment in pediatric patients with chronic or recurrent bronchopulmonary diseases. A total of 42 lower respiratory tract specimens and 11 paired plasma samples from 42 patients were analyzed for the presence of CMV DNA by real‐time PCR. The respiratory specimens were also screened for the presence of respiratory viruses and human herpesvirus 6 (HHV‐6) and 7 (HHV‐7) by PCR methods. Quantitative bacterial and fungal cultures were performed. IL‐6 levels in the …

Lung DiseasesMaleAdolescentmedicine.medical_treatmentRespiratory SystemCytomegalovirusAntibodies ViralReal-Time Polymerase Chain Reactionmedicine.disease_causePlasmachildrenRecurrencerespiratory virusesVirologymedicineHumansRespiratory systemChildInterleukin 6bronchopulmonary diseasesResearch ArticlesbiologyInterleukin-6human herpesvirus‐6Infantvirus diseasesImmunosuppressionCytomegalovirusIL‐6biology.organism_classificationVirologyInfectious DiseasesReal-time polymerase chain reactionmedicine.anatomical_structureChild PreschoolChronic DiseaseDNA ViralImmunologybiology.proteinFemaleHuman herpesvirus 6AntibodyResearch ArticleRespiratory tractJournal of Medical Virology
researchProduct

Latency versus persistence or intermittent recurrences: Evidence for a latent state of murine cytomegalovirus in the lungs

1997

The state of cytomegalovirus (CMV) after the resolution of acute infection is an unsolved problem in CMV research. While the term "latency" is in general use to indicate the maintenance of the viral genome, a formal exclusion of low-level persistent productive infection depends on the sensitivity of the assay for detecting infectious virus. We have improved the method for detecting infectivity by combining centrifugal infection of permissive indicator cells in culture, expansion to an infectious focus, and sensitive detection of immediate-early RNA in the infected cells by reverse transcriptase PCR. A limiting-dilution approach defined the sensitivity of this assay. Infectivity was thereby …

Lung DiseasesMuromegalovirusMolecular Sequence DataImmunologyCentrifugationGenome ViralViral Plaque AssayPolymerase Chain ReactionSensitivity and SpecificityMicrobiologylaw.inventionMiceMuromegalovirusRecurrencelawVirologyVirus latencymedicineAnimalsLatency (engineering)Cells CulturedPolymerase chain reactionVirus quantificationInfectivityMice Inbred BALB COrganizationsBase SequencebiologyRNAHerpesviridae Infectionsbiology.organism_classificationmedicine.diseaseVirologyVirus LatencyReverse transcription polymerase chain reactionInsect ScienceDNA ViralImmunologyFemaleResearch Article
researchProduct

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

2008

Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non–Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell–engag…

Lymphoma B-CellT-Lymphocytesmedicine.medical_treatmentT cellAntineoplastic AgentsLymphoma Mantle-CellImmunophenotypingImmunophenotypingRecurrenceAntibodies BispecificmedicineHumansCytotoxic T cellLymphocyte CountLymphoma FollicularB-LymphocytesMultidisciplinarybusiness.industryCancerImmunotherapymedicine.diseaseLeukemia Lymphocytic Chronic B-CellLeukemiamedicine.anatomical_structureImmunologyCancer researchBlinatumomabBone marrowbusinessImmunologic MemoryT-Lymphocytes Cytotoxicmedicine.drugScience
researchProduct

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

2021

Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa‐cel in the standard‐of‐care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa‐cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded accor…

Male0301 basic medicine:aminoácidos péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores de antígenos::receptores de antígenos de linfocitos T [COMPUESTOS QUÍMICOS Y DROGAS]Cancer Researchnon‐Hodgkin's lymphomaBest Overall Responsehematological cancer:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Non- Hodgkin's lymphomaGastroenterology0302 clinical medicineMedicine research:Other subheadings::/therapeutic use [Other subheadings]CàncerB-cell lymphomaRC254-282CancerOriginal ResearchReceptors Chimeric AntigenNeoplasms. Tumors. Oncology. Including cancer and carcinogensnon&#8208Standard of CareMiddle AgedPatologiaHodgkin&aposProgression-Free SurvivalCytokine release syndromeclinical cancer researchOncology:neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES]030220 oncology & carcinogenesisCytokinesFemaleLymphoma Large B-Cell Diffusenon-Hodgkin's lymphomamedicine.medical_specialtyReceptors Antigen T-CellCèl·lules B - Tumors - Tractament:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Investigació mèdicaReal world evidence03 medical and health sciencess lymphoma:Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma Non-Hodgkin::Lymphoma B-Cell::Lymphoma Large B-Cell Diffuse [DISEASES]Refractoryclinical observationsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingLeukapheresis:Amino Acids Peptides and Proteins::Proteins::Membrane Proteins::Receptors Cell Surface::Receptors Immunologic::Receptors Antigen::Receptors Antigen T-Cell [CHEMICALS AND DRUGS]AgedRetrospective Studies:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryTeràpia cel·lularClinical Cancer ResearchLeukapheresismedicine.diseaseMalaltia de HodgkinNon-Hodgkin's lymphomaLymphoma030104 developmental biologyHodgkin's diseaseNeoplasm Recurrence LocalbusinessCancer Medicine
researchProduct

Effects of DA-Phen, a dopamine-aminoacidic conjugate, on alcohol intake and forced abstinence

2016

The mesolimbic dopamine (DA) system plays a key role in drug reinforcement and is involved in the development of alcohol addiction. Manipulation of the DAergic system represents a promising strategy to control drug-seeking behavior. Previous studies on 2-amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (DA-Phen) showed in vivo effects as a DA-ergic modulator. This study was aimed at investigate DA-Phen effects on operant behavior for alcohol seeking behavior, during reinstatement following subsequent periods of alcohol deprivation. For this purpose, male Wistar rats were tested in an operant paradigm of self-administration; behavioral reactivity and anxiety like-behavior durin…

Male0301 basic medicineAlcohol DrinkingDopaminePhenylalaninemedia_common.quotation_subjectDopamine AgentsDrug-Seeking BehaviorAddictionSelf AdministrationAlcoholAnxietyPharmacologyDopamine derivativeCNS targeting03 medical and health sciencesBehavioral Neurosciencechemistry.chemical_compound0302 clinical medicineRecurrenceEmotionalityDopamineIn vivomedicineAnimalsRats Wistarmedia_commonEthanolAddictionCentral Nervous System DepressantsAbstinenceAlcoholismDisease Models Animal030104 developmental biologychemistryPharmacodynamicsOperant self-administration paradigmConditioning OperantAnxietymedicine.symptomPsychology030217 neurology & neurosurgeryDopaminergic neurotransmissionAlcohol Deterrentsmedicine.drugBehavioural Brain Research
researchProduct

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis

2017

AbstractThe extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE−) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent r…

Male0301 basic medicineBiochemical recurrenceOncologymedicine.medical_specialtyPathologyScienceprostate cancer he extranodal extension (ENE) perinodal adipose tissuenot knownArticle03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineJournal ArticleOdds RatioHumansMedicineperinodal adipose tissueNeoplasms Adipose TissueAgedProportional Hazards ModelsMultidisciplinarybusiness.industryProportional hazards modelQHazard ratioRProstateProstatic NeoplasmsCancerOdds ratioMiddle Agedprostate cancerPrognosismedicine.disease3. Good health030104 developmental biologyLymphatic Metastasis030220 oncology & carcinogenesisRelative riskhe extranodal extension (ENE)MedicineProstate surgeryLymph NodesNeoplasm Recurrence LocalbusinessScientific Reports
researchProduct

Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition

2017

AbstractPurpose: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20%–30%) undergo consecutive recurrences with poor outcome. We hypothesized that patients with 11q-loss may share a druggable molecular target(s) that can be exploited for a precision medicine strategy to improve treatment outcome.Experimental Design: SNP arrays were combined with next-generation sequencing (NGS) to precisely define the deleted region in 17 primary 11q-loss neuroblastomas and identify allelic variants in genes relevant for neuroblastoma etiology. We assessed PARP inhibitor olaparib in combination with other chemotherapy medications using both in vitro and in v…

Male0301 basic medicineCancer ResearchDNA repairAntineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsKaplan-Meier EstimatePoly(ADP-ribose) Polymerase InhibitorsBiologyModels BiologicalPolymorphism Single NucleotideImmunophenotypingOlaparibNeuroblastoma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRecurrenceCell Line TumorNeuroblastomaBiomarkers TumormedicineAnimalsHumansAllelesNeoplasm StagingCisplatinTemozolomideChromosomes Human Pair 11High-Throughput Nucleotide SequencingCancerDrug SynergismPrognosismedicine.diseaseXenograft Model Antitumor AssaysMolecular biologyDisease Models Animal030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisPARP inhibitorCancer researchFemaleChromosome DeletionHaploinsufficiencyBiomarkersmedicine.drugClinical Cancer Research
researchProduct